Form 4: Repare Therapeutics Director Bonita David P Acquires Stock Options

Director Bonita David P of Repare Therapeutics Inc. was granted stock options to purchase 27,200 common shares on June 17, 2024.

Summary

• On June 17, 2024, Bonita David P, a director of Repare Therapeutics Inc., was granted stock options.
• These options allow the director to purchase 27,200 common shares at an exercise price of $3.80 per share.
• The options vest in equal monthly installments over twelve months from the grant date, contingent upon continued service.
• The expiration date for these options is June 16, 2034.

Sentiment

Score: 6

Explanation: The document indicates a standard practice of granting stock options to directors, which is generally viewed neutrally. It suggests alignment of interests between management and shareholders.

Positives

• The grant of stock options to a director aligns their interests with those of the shareholders, incentivizing them to work towards the company's success.
• The vesting schedule encourages the director's continued service with the company.

Industry Context

Stock option grants are a common practice in the biotechnology industry to attract and retain key personnel, aligning their interests with the long-term success of the company.

Comparison to Industry Standards

• Stock option grants are a standard form of compensation for directors and executives in publicly traded companies, particularly in the biotech sector.
• The vesting schedule of 12 months is fairly typical, as it encourages continued service and commitment to the company's goals.
• Comparable companies in the biotech industry, such as BioNTech or Moderna, also utilize stock options as part of their compensation packages for directors and key employees.

Stakeholder Impact

• The stock option grant could potentially increase shareholder value if the director's performance leads to company growth.
• Employees may view the grant positively as it signals confidence in the company's future.

Key Dates